Ep. 4: Datopotamab Deruxtecan in EGFR-Mutated NSCLC: Community-Based Monitoring and Toxicity Management
Key Points
-
Datopotamab deruxtecan (Dato-DXd) can be safely monitored and rechallenged after low-grade toxicities without compromising efficacy.
-
Imaging frequency and interstitial lung disease (ILD) monitoring should be individualized based on symptoms and clinical context.
-
Early collaboration with ophthalmology or optometry supports safe management of cumulative ocular toxicities.
In the next segment of this Clinical Insights discussion, Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, were joined by Blanca A. Ledezma, NP, of UCLA Health; Aaron Lisberg, MD, of UCLA Health; and Sarah B. Sunshine, MD, of the University of Maryland School of Medicine. The panel focused on Dato-DXd’s emerging role as an important option for patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have progressed after EGFR tyrosine kinase inhibitors and platinum-based chemotherapy.
Imaging and ILD Monitoring in Clinical Practice
Although ILD monitoring in clinical trials often requires imaging every 6 weeks, real-world imaging schedules are more flexible. Scans are typically obtained every 8 to 12 weeks for clinically stable patients who are responding to therapy. Imaging frequency may increase if patients develop respiratory symptoms or if prior scans lead to concern for pneumonitis.
Patients with suspected or confirmed ILD are monitored closely, including earlier repeat imaging, frequent clinic visits, and virtual or phone-based follow-up while receiving corticosteroids. The goal is to ensure improved symptoms and intervene early if respiratory status worsens. Close surveillance allows clinicians to balance safety with continued access to an effective therapy.
Dosing, Administration, and Supportive Care
Dato-DXd is administered intravenously at a standard dose of 6 mg/kg every 3 weeks. If dose reductions are required, patients are reduced first to 4 mg/kg and then to 3 mg/kg, with permanent discontinuation if the second reduction is not tolerated. The initial infusion is given over a longer duration, with subsequent infusions typically administered over 30 minutes.
Patients are observed for 1 hour following the first 2 infusions and for 30 minutes thereafter if treatment is well tolerated. Because Dato-DXd is classified as highly emetogenic, antiemetic prophylaxis is recommended and may include a 5-HT3 antagonist, a neurokinin-1 receptor antagonist, dexamethasone, and olanzapine, along with antihistamines to reduce infusion reactions, according to institutional practice.
Ocular Toxicities and Multidisciplinary Collaboration
Ocular toxicity represents a distinct consideration with Dato-DXd and requires proactive patient education and multidisciplinary care. Baseline evaluation by an ophthalmologist or optometrist around the start of treatment is encouraged, though therapy should not be delayed in the absence of ocular symptoms.
Most ocular toxicities are low grade and cumulative, commonly presenting as dry eyes or increased tearing. Patients are counseled on regular use of preservative-free artificial tears and monitored closely for symptom progression. Symptoms that affect quality of life or do not respond to conservative measures typically prompt referral to an ophthalmologist.